Amicus Therapeutics, Inc. (FOLD) Shares Bought by TD Asset Management Inc.
TD Asset Management Inc. boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 86.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 225,454 shares of the biopharmaceutical company’s stock after purchasing an additional 104,294 shares during the period. TD Asset Management Inc. owned about 0.14% of Amicus Therapeutics worth $3,400,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Strs Ohio purchased a new position in Amicus Therapeutics in the third quarter worth $102,000. Birchview Capital LP purchased a new position in Amicus Therapeutics in the third quarter worth $151,000. Teacher Retirement System of Texas boosted its position in Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in Amicus Therapeutics in the second quarter worth $124,000. Finally, Aperio Group LLC boosted its position in Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,663 shares during the last quarter.
Shares of Amicus Therapeutics, Inc. (FOLD) opened at $12.89 on Friday. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. equities analysts predict that Amicus Therapeutics, Inc. will post -1.56 EPS for the current year.
In related news, insider Hung Do sold 50,194 shares of the business’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $715,264.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Daphne Quimi sold 7,000 shares of the business’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 680,437 shares of company stock worth $9,734,522. Corporate insiders own 3.40% of the company’s stock.
Several research analysts have weighed in on the company. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Goldman Sachs Group reissued a “neutral” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research report on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.81.
ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics, Inc. (FOLD) Shares Bought by TD Asset Management Inc.” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/08/amicus-therapeutics-inc-fold-shares-bought-by-td-asset-management-inc.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.